Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ProMiDis

Financiado

Cerrado

A unified drug discovery platform for protein misfolding diseases

It is now widely recognized that a variety of major diseases, such as Alzheimer’s disease, Huntington’s disease, systemic amyloidosis, cystic fibrosis, type 2 diabetes etc., are characterized by a common molecular origin: the misf... ver más

30/06/2026

BIOMEDICALSCIENCES...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-02-01

ERC-2018-COG: ERC Consolidator Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

BIOMEDICALSCIENCES RESEARCH...

877.33K€ | Lider

FERRER INTERNACIONAL

2.07M€ | Participante

NATIONAL HELLENIC RESEARCH F...

1.09M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PRe-ART-2T Predictive REagent-Antibody Replacement Technology stage 2-T... 800K€ Cerrado

POCKETSPPI Discovering and exploiting hidden pockets at protein protein... 100K€ Cerrado

PTQ-09-01-01032 Generación de una herramienta de cribado virtual para la ide... 55K€ Cerrado

EXSCALATE4CoV EXaSCale smArt pLatform Against paThogEns for Corona Virus 3M€ Cerrado

PID2021-125946OB-I00 INGENIERIA DE GANANCIA DE FUNCION DE PROTEINAS IN SILICO PAR... 163K€ Cerrado

PROTEOSCREEN Development of Proteomimetics as Drug Discovery Screening To... 153K€ Cerrado

Duración del proyecto: 88 meses Fecha Inicio: 2019-02-01
Fecha Fin: 2026-06-30

Líder del proyecto

EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto It is now widely recognized that a variety of major diseases, such as Alzheimer’s disease, Huntington’s disease, systemic amyloidosis, cystic fibrosis, type 2 diabetes etc., are characterized by a common molecular origin: the misfolding of specific proteins. These disorders have been termed protein misfolding diseases (PMDs) and the vast majority of them remain incurable. Here, I propose the development of a unified approach for the discovery of potential therapeutics against PMDs. I will generate engineered bacterial cells that function as a broadly applicable discovery platform for compounds that rescue the misfolding of PMD-associated proteins (MisPs). These compounds will be selected from libraries of drug-like molecules biosynthesized in engineered bacteria using a technology that allows the facile production of billions of different test molecules. These libraries will then be screened in the same bacterial cells that produce them and the rare molecules that rescue MisP misfolding effectively will be selected using an ultrahigh-throughput genetic screen. The effect of the selected compounds on MisP folding will then be evaluated by biochemical and biophysical methods, while their ability to inhibit MisP-induced pathogenicity will be tested in appropriate mammalian cell assays and in established animal models of the associated PMD. The molecules that rescue the misfolding of the target MisPs and antagonize their associated pathogenicity both in vitro and in vivo, will become drug candidates against the corresponding diseases. This procedure will be applied for different MisPs to identify potential therapeutics for four major PMDs: Huntington’s disease, cardiotoxic light chain amyloidosis, dialysis-related amyloidosis and retinitis pigmentosa. Successful realization of ProMiDis will provide invaluable therapeutic leads against major diseases and a unified framework for anti-PMD drug discovery.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores